New drug combo shows promise for Hard-to-Treat cancers
NCT ID NCT06470763
First seen Apr 18, 2026 · Last updated May 22, 2026 · Updated 6 times
Summary
This study tests a new drug called ANV600, alone or with another drug (pembrolizumab), in 240 adults with advanced solid tumors that have not responded to other treatments. The goal is to check safety and see if the drug shrinks tumors. Participants must be in fairly good health and have measurable tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CEPCM - AP-HM Hopital de la Timone
Marseille, France
-
Cantonal Hospital St Gallen
Sankt Gallen, Switzerland
-
Charite Universitaetsmedizin Berlin
Berlin, Germany
-
Clinica Universidad de Navarra - Pamplona
Pamplona, Spain
-
Cliniques Universitaires Saint-Luc
Brussels, Belgium
-
Ente Ospedaliero Cantonale - Istituto Oncologico della Svizzera Italiana
Bellinzona, Switzerland
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
INCLIVA Foundation
Valencia, Spain
-
Institut Bergonie
Bordeaux, France
-
Institut Gustave Roussy
Villejuif, France
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Krankenhaus Nordwest - Institut für Klinisch-Onkologische Forschung (IKF)
Frankfurt, Germany
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL)
Amsterdam, Netherlands
-
Oncopole Claudius Regaud, Toulouse
Toulouse, France
-
START Madrid CIOCC
Madrid, Spain
-
Universitaetsmedizin der Johannes Gutenberg - Universitaet Mainz
Mainz, Germany
-
Vall d'Hebron Institute of Oncology (VHIO)
Barcelona, Spain
Conditions
Explore the condition pages connected to this study.